Latest News

A Big Thank You

A Big Thank You

Update: Thank you to everyone who supported our Special Appeal as shown on Channel 9’s A Current Affair in December 2016. The result from the Phase 1 clinical trial have now been published and negotiations are continuing in relation to the conduct of a phase II trial.

Read More

ADRI Supports Asbestos Awareness Month

As November is Asbestos Awareness Month many councils and stakeholder groups across Australia support this campaign by holding events to raise awareness of the dangers of asbestos.  On Tuesday 22nd November the ADRI presented lunch time information sessions to Concord Hospital staff not only to raise awareness of the dangers…

Read More

Asbestos Awareness Month 1-30 November

‘Get to kNOw Asbestos this November’ The Asbestos Awareness Campaign aims to educate Australian about the dangers of asbestos in and around homes because Australia has one of the highest rates of asbestos-related diseases in the world. With asbestos-related diseases continuing to increase among Australians as a direct result of…

Read More

ADSS Symposium 2016 Asbestos Related Diseases Here and Now

Professor Nico van Zandwijk was invited by the Asbestos Disease Support Society (adss) to present at the 2016 Symposium on Asbestos related diseases Here and Now in Brisbane on the 19th October 2016. Professor van Zandwijk spoke about the latest developments in mesothelioma treatment and research to audience of 200.…

Read More

Dr Karin Schelch, postdoc

Karin Schelch joined ADRI in April 2016 after graduating with a PhD from the Medical University of Vienna. She has worked extensively on the role of growth factors in mesothelioma, and is applying her experience to many projects at ADRI.

Read More

ADRF Appoints New ADRI Director

The Board of the Asbestos Diseases Research Foundation (ADRF) is pleased to announce that Prof Ken Takahashi has been appointed as the new ADRI Director. He will take over from Prof Nico van Zandwijk – the Institute’s inaugural Director who has held the position since 2008 – in February of…

Read More

New article on TargomiRs

ADRI scientists and collaborators have published a special report on the clinical development of their microRNA-based treatment for mesothelioma. This report describes microRNA replacement therapy for cancer and the concept behind TargomiRs in the MesomiR-1 trial. It appears in the journal Epigenomics and can be found here

Read More

Latest biomarker research published

ADRI scientists have recently published an article in the British Journal of Cancer describing work on a blood biomarker for malignant pleural mesothelioma. It focuses on fibulin-3, a protein secreted by mesothelioma cells into the blood of patients. See here for a link to the paper.

Read More

New microRNA research paper published

A paper by ADRI scientists describing the role of a potential suppressor microRNA in malignant pleural mesothelioma biology has been published in the journal Oncotarget. Please see here for a link to the article.

Read More

Early results from MesomiR 1 trial published

The first results from the MesomiR 1 trial, a phase I clinical trial of a targeted delivery of a microRNA-based therapy, were published yesterday in the American Journal of Respiratory and Critical Care Medicine The trial is a collaboration between ADRI, the Sydney-based biotech company EnGeneIC Ltd and three hospitals…

Read More